CHAMGAP
Verdict No. 3100 · Search date 2026-09-15 · Methodology v1.0

Oral single-active-ingredient pantothenic acid supplementation,
does it really help with Reduction in LDL-C concentration in adults with elevated LDL-C?

30-Second Summary
?
Evidence Grade ? · Safety caution
ChatGPT source review and self-verification · Codex technical integration
The evidence cutoff is 2026-09-15. Targeted web searches, citation chaining and accessible primary material were used; some database/API, registry and full-text access attempts failed. Worldwide absence, including unpublished studies, is therefore not guaranteed. New monotherapy trials, exact salt/product data, LDL-C tables, denominators, analysis plans, corrections or retractions will trigger a cumulative revision history at the same assigned ID and URL.
Caution. High-dose pantothenic acid can cause diarrhea or gastrointestinal distress. The NIH example of 10 g/day is not a toxicity threshold or dosing recommendation, and the adult adequate intake of 5 mg/day is not a lipid-treatment dose. No established upper limit does not mean unlimited safety. Long-term high-dose LDL-C use and safety in pregnancy, lactation, children and liver/kidney disease remain unverified. No known clinically relevant drug interactions does not rule out all interactions. Pantethine-specific bleeding or anticoagulant cautions were not copied to pantothenic acid. Research and nutritional amounts are not personal dosing instructions. [S06]
What the
research shows
The currently verified material does not establish that oral pantothenic acid alone lowers LDL-C more than placebo or usual care on the same background treatment. Related human lipid trials exist, but their intervention is pantethine or a multicomponent product, so their results were not attributed to pantothenic acid alone. ? is a current judgment of no directly eligible result verified within the recorded search, not no effect or worldwide absence of studies. [S101][S105]
What the
ads claim
Nutritional functions of pantothenic acid, lipid metabolism in animals, B-complex absorption and LDL lowering by the different molecule pantethine do not establish this monotherapy. LDL-C is a surrogate; it does not establish fewer cardiovascular events or replacement of lipid-lowering medicines. [S103][S105][S101]

Four separate assessment dimensions

Effect direction and sizeNo directly eligible LDL-C comparison for pantothenic-acid monotherapy verified
Evidence certainty? is scoped uncertainty, not no effect
ApplicabilityAdults with elevated LDL-C; oral pantothenic acid as the sole active ingredient; placebo or usual care on matched background treatment
SafetyCaution

B / S / null / null / null / null / null; score and strength count null

*

Useful facts when choosing a product

  • The eligible single product's manufacturing origin, brand, exact salt, purity, batch, tablet/capsule, release type, dose, frequency and duration are unverified.
  • No verified inputs were obtained to convert calcium-pantothenate mass into pantothenic-acid mass, and clinical equivalence of the forms was not asserted. [S06]
  • The mechanistic pantothenic-acid paper used adult male mice and primary adipocytes, not a controlled human LDL-C trial. [S103]
  • The inspected NCT03444155 protocol compares B-complex formulations. Registrations and reports were not counted as eligible single-ingredient trials. [S105][S106]
ID

Chamgap Semantic Classification Code

Permanent code issued

S.pantothenic-acid.oral.ldl-cholesterol.reduce.placebo

Substances and nutrients > Pantothenic acid (vitamin B5), sole active ingredient > Oral > LDL cholesterol > Reduction claim > Placebo

Bound to the LDL-C claim for oral pantothenic acid monotherapy. Pantethine and B-complex products are distinct interventions; a directly eligible pantothenic-acid result remains unverified. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.

Download semantic index (JSON) · Codebook v1

Exact Claim Classification

These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.

Intervention classS · Supplement or nutraceutical
Canonical ingredient or interventionPantothenic acid (vitamin B5), sole active ingredient; calcium salt assessed separately
Source or part usedNot verified — eligible monotherapy manufacturing origin, purity and batch unverified
Formulation or processingSingle-active oral preparation; exact salt, tablet/capsule and release type unverified
RouteOral
DoseNot verified — eligible pantothenic-acid monotherapy dose and frequency unverified
DurationNot verified — eligible treatment duration and timing unverified
PopulationAdults with elevated LDL-C; actual diagnostic threshold, baseline, medicines and deficiency unverified
Effect or conditionReduction in LDL-C concentration
Primary endpointBetween-group LDL-C concentration change (mg/dL or mmol/L); endpoint difference separate, actual eligible results unverified
ComparatorPlacebo/usual care on matched background treatment; actual composition and common treatments unverified
Duplicate-detection keypantothenic-acid|oral-single-active-exact-salt-not-verified|dose-not-verified|adults-with-elevated-ldl-c|ldl-c-between-group-change|duration-not-verified|placebo-or-usual-care-on-matched-background-treatment
01

What the research actually shows

For this fixed question, LDL-C baseline, change and endpoint values, arm-specific analysis denominators, between-group change difference, CI, P value and assessment time remain unverified. Information distinguishing directly measured LDL from formula-calculated LDL is also unavailable. No conversion between mmol/L and mg/dL or reconstruction from graphs was performed. Adjacent pantethine results were not inserted as pantothenic-acid data. [S101]

02

Why this is classified as ?

Applying the supplied original rubric and calculator's direct-human-evidence gate to this single claim yields ? with null score. The 7 axes are B / S / null / null / null / null / null. LDL-C is laboratory surrogate S. The last five axes and strength count are unscored, not 0. Neither pantethine's C with 52 points nor the C in the skin composite record was inherited.

Counterpoint. Without a verified direct monotherapy trial, no repeated refutation or 0 effect is asserted. Nonhuman research, pantethine, B-complex products, enriched margarine and multicomponent lipid-product leads were separated for their respective reasons. Inaccessible full texts or registrations were not counted as negative trials. [S103][S105][S107][S108]

Rejudgment record. No directly eligible controlled single-ingredient LDL-C result verified — Original rubric stage 0, LDL-C endpoint S; subsequent axes not applied

Stored scoring profile
EndpointSSurrogate marker - laboratory or imaging measures

Stored derived and displayed grades match; this is not a current recalculation or validity check (?).

Review performed and remaining limitations

Pantethine trials, nonhuman mechanistic work and a B-complex protocol were separated, with duplicate boundaries checked against records 366, 028 and 3099

Directly eligible pantothenic-acid monotherapy results, exact salt, formulation, dose, duration, population threshold and between-group LDL-C values remain unverified

03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Evans 2014 pantethine trial — a different molecule from pantothenic acidTriple-blinded placebo- and diet-controlled pantethine trial32 randomized and 24 completed; excluded from direct pantothenic-acid evidenceFunded by Daiichi Fine Chemical Co Ltd; information pertains to the pantethine trialNot eligible for this single-ingredient LDL-C questionLDL results exist but are excluded from direct efficacy because the molecule differsExcluded from direct grading
Zhao nonhuman mechanistic study of pantothenic-acid metabolismMice and primary adipocytes; possibly related preprintAdult male mice and primary adipocytes; no human analysis denominator appliesNot verified from the accessed abstractNot eligible for this single-ingredient LDL-C questionNonhuman mechanistic findings not transferred to human monotherapy LDL efficacyExcluded from direct grading
NCT03444155 protocol comparing natural and synthetic B-complex productsB-complex study protocolActual randomized count and results unverified; no pantothenic-acid monotherapy denominatorNot extracted for this excluded protocolNot eligible for this single-ingredient LDL-C questionMulticomponent intervention/comparator; no direct single-ingredient LDL result verifiedExcluded from direct grading
§

Receipt — 15 References

Evidence access cutoff: 2026-09-15. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.

NIH Office of Dietary Supplements. Pantothenic Acid — Health Professional Fact Sheet
checked
Evans et al. 2014. Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: a triple-blinded placebo and diet-controlled investigation
checked
PubMed record for Evans et al. 2014
checked
Zhao et al. Pantothenic Acid Alleviates Fat Deposition and Inflammation by Suppressing the JNK/P38 MAPK Signaling Pathway
checked
Preprint lead: Pantothenic acid alleviates fat deposition by preventing activation of the JNK/P38 MAPK pathway
checked
NCT03444155 protocol and statistical plan, version 1.2 dated 2017-04-13: natural versus synthetic vitamin B complex
checked
ClinicalTrials.gov landing page for NCT03444155
checked
Gaddi A, Descovich GC, Noseda G, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipidemia. Atherosclerosis. 1984;50(1):73-83. PMID: 6365107. DOI: 10.1016/0021-9150(84)90009-1.
checked
McRae MP. Treatment of hyperlipoproteinemia with pantethine: a review and analysis of efficacy and tolerability. Nutr Res. 2005;25(4):319-333. DOI: 10.1016/j.nutres.2004.12.009.
checked
Rumberger JA, Napolitano J, Azumano I, Kamiya T, Evans M. Pantethine, a derivative of vitamin B5 used as a nutritional supplement, favorably alters low-density lipoprotein cholesterol metabolism in low- to moderate-cardiovascular risk North American subjects: a triple-blinded placebo and diet-controlled investigation. Nutr Res. 2011;31(8):608-615. PMID: 21925346. DOI: 10.1016/j.nutres.2011.08.001.
checked
Legacy 028: pantothenic acid × skin/hair, historical composite
checked
Completed R01-021: oral pantothenic acid monotherapy × inflammatory acne lesions
checked
Discovery lead: Influence of Several Lipids on Human Serum Cholesterol (Part 9), enriched margarine with pantothenic acid and vitamin B6
checked
Discovery lead: Kim et al. mixed nutraceutical / LDL stability study, Nutrients 2013;5:5218
checked
Discovery lead: 2026 dyslipidemia guideline key messages
checked
Content ready; identifier assignment, technical checks and deployment remain separate
Technical integration by: Codex · Evidence date: 2026-09-15 · Corrections: none

Cite this verdict

Oral pantothenic acid monotherapy × elevated LDL-C concentration Evidence Grade ? card
[Chamgap] Oral pantothenic acid monotherapy × elevated LDL-C concentration — Evidence Grade ?. 15 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/oral-pantothenic-acid-monotherapy-elevated-ldl-cholesterol/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.